{"entity":{"id":"nct06970782","kind":"trial","name":"Vebreltinib Plus PLB1004 Versus Platinum-based Doublet Chemotherapy in Patients With EGFRm, MET+, Locally Advanced or Metastatic NSCLC Following EGFR-TKI Failur","aka":["KYLIN-3"],"tldr":"A phase 3 trial of vebreltinib and pemetrexed in lung cancer, run by Avistone Biotechnology Co., Ltd., not yet recruiting.","summary":"Vebreltinib Plus PLB1004 Versus Platinum-based Doublet Chemotherapy in Patients With EGFRm, MET+, Locally Advanced or Metastatic NSCLC Following EGFR-TKI Failure is a phase 3, randomised interventional study registered as NCT06970782 by Avistone Biotechnology Co., Ltd., with a registry enrolment figure of 278 participants, started 2025-05-15 and due to reach its primary completion in 2027-12-31. Interventions recorded: Vebreltinib; PLB1004; Pemetrexed plus Carboplatin or Cisplatin. Conditions listed: Non-Small-Cell Lung Cancer. Primary outcome: Progression-Free Survival (PFS) by BICR. Lung eligibility wording from the registry: \"Histologically or cytologically confirmed locally advanced or metastatic NSCLC (stage IIIB\\~IV)\". No results are recorded here; the registry entry is the source.","status":"planned","asOf":"2026-09-25","links":[{"label":"ClinicalTrials.gov NCT06970782","url":"https://clinicaltrials.gov/study/NCT06970782"}],"tags":["ctgov-ingest","lung-deep-dive"],"related":[],"cancers":["egfr-mutant-nsclc","met-altered-nsclc"],"sections":[],"technologies":["cytotoxic-chemotherapy"],"targets":[],"drugs":["vebreltinib","pemetrexed"],"companies":["avistone-biotechnology"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT06970782","phase":"3","setting":"A Randomized, Controlled, Open Label, Multicenter Phase III Study to Evaluate the Efficacy and Safety of Vebreltinib in Combination With PLB1004 Versus Platinum-based Doublet Chemotherapy in Patients With EGFR Mutations, MET Amplification and/or Overexpression, Locally Advanced or Metastatic Non-Small Cell Lung Cancer Following EGFR-TKI Treatment Failure","sponsor":"Avistone Biotechnology Co., Ltd.","enrolled":278,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct06970782/","neighbours":{"cancer":[{"id":"egfr-mutant-nsclc","kind":"cancer","name":"EGFR-mutated non-small-cell lung cancer","route":"/cancers/egfr-mutant-nsclc/"},{"id":"met-altered-nsclc","kind":"cancer","name":"MET exon 14 and MET-amplified non-small-cell lung cancer","route":"/cancers/met-altered-nsclc/"}],"technology":[{"id":"cytotoxic-chemotherapy","kind":"technology","name":"Cytotoxic chemotherapy","route":"/technologies/cytotoxic-chemotherapy/"}],"drug":[{"id":"pemetrexed","kind":"drug","name":"Pemetrexed","route":"/drugs/pemetrexed/"},{"id":"vebreltinib","kind":"drug","name":"Vebreltinib","route":"/drugs/vebreltinib/"}],"company":[{"id":"avistone-biotechnology","kind":"company","name":"Avistone Biotechnology","route":"/companies/avistone-biotechnology/"}],"term":[{"id":"lung-trials-open-today","kind":"term","name":"Lung cancer trials open today (registry snapshot)","route":"/terms/lung-trials-open-today/"}]}}